Clinical Trial Update: Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia [NA]

View source ↗

Summary

Clinical trial of Withania Somnifera as an immunomodulator and anti-inflammatory agent for schizophrenia and schizoaffective disorder has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Withania Somnifera (Withania somnifera)

Snippet

Sponsor: K.N. Roy Chengappa | Conditions: Schizophrenia, Schizoaffective Disorder | NA | Status: COMPLETED | Results posted: 2017-11-22